Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 28, 2026 · Filed Oct 29, 2026
The CEO of Actuate Therapeutics paid $50K out of pocket for Actuate Therapeutics shares. It was the first purchase in over a year. Shares held went up 47% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$50,000
Shares × reported transaction price
$25K–$100K
+46.7%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
None in 16 months of history
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
Closed at $0.3833 on Oct 28, 2026, at its 52-week low, after a 62% drop over the previous 30 trading days
52-week range $0.3833 (Oct 28, 2026) to $7.63 (Nov 28, 2025), 0% of the way up, from 251 adjusted closes. 30 trading days earlier: $0.9974 on Sep 16, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
The first open-market purchase by any ACTU insider since Jun 2025. Daniel M Schmitt's first open-market purchase of ACTU in filings since 2024
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.9% | −2.7% | +0.8% |
Past results only. Not a forecast.
Insider filing
Traded Oct 28 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Oct 28 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Oct 28 · filed 5 days later
Compensation award — excluded from discretionary-purchase analysis.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
